Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05959057 · ClinicalTrials.gov registry record · NA
ERr 731® Formulation Evaluation
A NA study, sponsored by Metagenics.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT05959057: Completed NA study, sponsored by Metagenics.
NCT05959057 is a NA study that has completed, run by Metagenics. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05959057, a NA study, has completed, sponsored by Metagenics.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
A comparison of an enteric coated and micro-coated formulation of ERr 731®
Primary Outcome
Frequency of symptoms of gastrointestinal nature collected on a custom questionnaire
Interventions
- DIETARY_SUPPLEMENT ERr 731 - Micro-coated
- DIETARY_SUPPLEMENT ERr 731 - Enteric coated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-05-24 |
| Est. Completion | 2023-08-18 |
| Phase | NA |
What the finished NCT05959057 record still lists
NCT05959057 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which ERr 731 - Micro-coated is the first listed.
NCT05959057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05959057 about?
NCT05959057 is a clinical study titled "ERr 731® Formulation Evaluation". A comparison of an enteric coated and micro-coated formulation of ERr 731®
What is the current status of trial NCT05959057?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2023-05-24. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT05959057?
The interventions under investigation include: ERr 731 - Micro-coated (DIETARY_SUPPLEMENT), ERr 731 - Enteric coated (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05959057?
This trial is sponsored by Metagenics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05959057's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI